Meridian Bioscience (Meridian Bioscience) EBIT per Share : $1.26 (TTM As of Sep. 2022)

View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience EBIT per Share?

Meridian Bioscience's EBIT per Share for the three months ended in Sep. 2022 was $0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $1.26.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Meridian Bioscience's EBIT per Share or its related term are showing as below:

VIVO's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -1.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Meridian Bioscience's EBIT for the three months ended in Sep. 2022 was $4.9 Mil.

Meridian Bioscience EBIT per Share Historical Data

The historical data trend for Meridian Bioscience's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience EBIT per Share Chart

Meridian Bioscience Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

EBIT per Share

Get a 7-Day Free Trial

0.75

0.78

1.43

2.10

1.25

Meridian Bioscience Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT per Share	Get a 7-Day Free Trial															0.19	0.46	0.83	-0.14	0.11

Meridian Bioscience EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Meridian Bioscience's EBIT per Share for the fiscal year that ended in Sep. 2022 is calculated as

	EBIT per Share		(A: Sep. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	55.506	/	44.375
=	1.25

Meridian Bioscience's EBIT per Share for the quarter that ended in Sep. 2022 is calculated as

	EBIT per Share		(Q: Sep. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	4.853	/	44.810
=	0.11

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.26

Meridian Bioscience (NAS:VIVO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Meridian Bioscience EBIT per Share Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Meridian Bioscience (Meridian Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3471 River Hills Drive, Cincinnati, OH, USA, 45244

Website

https://www.meridianbioscience.com

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Executives

Julie Diana Smith	officer: Sr VP, Controller, PAO	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny	director, officer: Chief Executive Officer	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller	officer: EVP & CFO	ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare	officer: Interim CFO & Chief Acctg Off	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii	director	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna	officer: Executive VP-Diagnostics	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams	director	C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini	officer: Exec VP, Operations & IS	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen	officer: EVP, Bus. Development/Strategy	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien	officer: EVP, Life Science	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244